$OVTZ
OCULUS VISIONTECH INC.

2021 Q2 Form 10-Q Financial Statement

#000143774921011821 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $122.1K $83.41K $71.79K
YoY Change 229.3% 16.18% 36.27%
% of Gross Profit
Research & Development $147.4K $132.7K $1.577K
YoY Change 317.3% 8316.23%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $269.6K $216.1K $73.37K
YoY Change 272.24% 194.6% 39.27%
Operating Profit -$483.7K -$393.6K -$73.37K
YoY Change 473.04% 436.52% 39.27%
Interest Expense $0.00 $0.00 $100.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $96.00
YoY Change
Pretax Income -$483.7K -$393.6K -$73.24K
YoY Change 473.02% 437.44%
Income Tax
% Of Pretax Income
Net Earnings -$483.7K -$393.6K -$73.27K
YoY Change 473.04% 437.23% 39.08%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$5.354K -$4.549K -$1.054K
COMMON SHARES
Basic Shares Outstanding 91.42M 86.52M 67.02M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.063M $298.6K $326.9K
YoY Change 252.3% -8.66% 5450.59%
Cash & Equivalents $3.063M $298.6K $326.9K
Short-Term Investments
Other Short-Term Assets $12.86K $2.800K $1.130K
YoY Change 318.89% 147.79% -12.4%
Inventory
Prepaid Expenses $7.500K $1.000K
Receivables
Other Receivables
Total Short-Term Assets $3.076M $301.4K $328.1K
YoY Change 252.54% -8.12% 4471.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets -$4.00 $2.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $3.076M $301.4K $328.1K
Total Long-Term Assets -$4.00 $2.00 $0.00
Total Assets $3.076M $301.4K $328.1K
YoY Change 8.33% -8.12% 4471.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $59.31K $53.58K $23.20K
YoY Change 14.26% 130.94% -53.32%
Accrued Expenses $0.00 $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $195.1K $189.3K $153.0K
YoY Change 7.67% 23.73% -80.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $195.1K $189.3K $153.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $195.1K $189.3K $153.0K
YoY Change 7.67% 23.73% -80.76%
SHAREHOLDERS EQUITY
Retained Earnings -$45.04M -$44.55M -$41.46M
YoY Change 8.41% 7.46% 0.52%
Common Stock $47.50M $44.25M $41.63M
YoY Change 8.48% 6.28% 2.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.881M $112.1K $175.0K
YoY Change
Total Liabilities & Shareholders Equity $3.076M $301.4K $328.1K
YoY Change 8.33% -8.12% 4471.63%

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$483.7K -$393.6K -$73.27K
YoY Change 473.04% 437.23% 39.08%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$297.9K -$191.6K -$55.52K
YoY Change -13.58% 245.05% -17782.17%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.062M $0.00
YoY Change 296.13%
NET CHANGE
Cash From Operating Activities -297.9K -$191.6K -55.52K
Cash From Investing Activities 0.000 $0.00
Cash From Financing Activities 3.062M $0.00
Net Change In Cash 2.764M -$191.6K -55.52K
YoY Change 409.57% 245.05% -17782.17%
FREE CASH FLOW
Cash From Operating Activities -$297.9K -$191.6K -$55.52K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001107280
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
91422569
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
OCULUS VISIONTECH INC.
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Security12b Title
Security12bTitle
Common stock - no par value; Preferred stock - no par value
CY2021Q1 dei Trading Symbol
TradingSymbol
ovtz
CY2021Q1 ovtz Working Capital Deficit
WorkingCapitalDeficit
112075
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
53578
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
32329
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
53578
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16670
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
15659
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
177490
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
177490
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
CY2021Q1 us-gaap Assets
Assets
301412
CY2020Q4 us-gaap Assets
Assets
496272
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298611
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
490190
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
490190
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
382452
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86522569
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86522569
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
44250747
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
298611
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
326930
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-191579
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-55522
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86522569
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86522569
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
44073257
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
393620
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
73365
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
135759
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
135738
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1966939
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2020Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2021Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1801
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
5052
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
21249
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
17773
CY2021Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
21
CY2020Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-163
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3281
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-137
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
96
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
301412
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
168067
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-191579
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55522
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-393620
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-2772484
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-192865
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-73269
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
96
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-393620
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-73365
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
496272
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
189337
CY2021Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2020Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
250000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
250000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2801
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6082
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1030
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
132724
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1577
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44552800
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44159180
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67022568
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
83406
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
71788
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
177490
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
112075
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
328205
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
248303
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
175034
CY2021Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
414128
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
414128
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86522569

Files In Submission

Name View Source Status
0001437749-21-011821-index-headers.html Edgar Link pending
0001437749-21-011821-index.html Edgar Link pending
0001437749-21-011821.txt Edgar Link pending
0001437749-21-011821-xbrl.zip Edgar Link pending
ex_248745.htm Edgar Link pending
ex_248746.htm Edgar Link pending
ex_248747.htm Edgar Link pending
ex_248748.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ovtz-20210331.xml Edgar Link completed
ovtz-20210331.xsd Edgar Link pending
ovtz-20210331_cal.xml Edgar Link unprocessable
ovtz-20210331_def.xml Edgar Link unprocessable
ovtz-20210331_lab.xml Edgar Link unprocessable
ovtz-20210331_pre.xml Edgar Link unprocessable
ovtz20210331_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending